You are here: Home 
Categories Prostate Cancer
Categories Prostate Cancer Combination immunotherapy with prostate GVAX and ipilimumab: Safety and toxicity - Abstract
Combination immunotherapy with prostate GVAX and ipilimumab: Safety and toxicity - Abstract
Published on 17 August 2012
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a Phase 1 dose-escalation trial.
To read more, a FREE Urotoday registration is required. Click here to register or login above.To read UIJ content, a separate subscription is required.
Tags:
